BBNA
CORT icon

Bremer Bank National Association’s Corcept Therapeutics CORT Stock Holding History

Bremer Bank National Association’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,015
Closed -$50K – 326
2019
Q1 		$50K Buy
+4,015
New +$49.9K 0.01% 451

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bremer Bank National Association's CORT Position: Q2 2019 in Review

Bremer Bank National Association sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 4,015 shares — an estimated $50K sold.

Bremer Bank National Association first reported a position in CORT in Q1 2019 and held it in 1 quarter. The position peaked at $50K in Q1 2019. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

  • Bremer Bank National Association reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Bremer Bank National Association sold 4,015 Corcept Therapeutics shares in Q2 2019, an estimated $50K.
  • Bremer Bank National Association first reported a position in Corcept Therapeutics in Q1 2019 and held it in 1 quarter.
  • Bremer Bank National Association's Corcept Therapeutics position peaked at $50K in Q1 2019.
  • 183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Bremer Bank National Association's 13F filing for Q2 2019, filed 13 Aug 2019.